<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04024202</url>
  </required_header>
  <id_info>
    <org_study_id>PPOC 15-27</org_study_id>
    <nct_id>NCT04024202</nct_id>
  </id_info>
  <brief_title>Data Registry of Auto Immune Hemolytic Anemia</brief_title>
  <acronym>DRAIHA</acronym>
  <official_title>The DRAIHA Study: Data Registry of AutoImmune Hemolytic Anemia, to Improve Diagnostic Testing for the Development of Personalized Treatment Protocols in AIHA Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanquin Research &amp; Blood Bank Divisions</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haga Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Isala</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jeroen Bosch Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Onze Lieve Vrouwe Gasthuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spaarne Gasthuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amsterdam University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanquin Plasma Products BV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanquin Research &amp; Blood Bank Divisions</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In autoimmune hemolytic anemia (AIHA) auto-antibodies directed against red blood cells (RBCs)
      lead to increased RBC clearance (hemolysis). This can result in a potentially
      life-threatening anemia. AIHA is a rare disease with an incidence of 1-3 per 100,000
      individuals. An unsolved difficulty in diagnosis of AIHA is the laboratory test accuracy. The
      current 'golden standard' for AIHA is the direct antiglobulin test (DAT). The DAT detects
      autoantibody- and/or complement-opsonized RBCs. The DAT has insufficient test characteristics
      since it remains falsely negative in approximate 5-10% of patients with AIHA, whereas a
      falsely positive DAT can be found in 8% of hospitalized individuals. Also apparently healthy
      blood donors can have a positive DAT. The consequences of DAT positivity are not well known
      and may point to early, asymptomatic disease, or to another disease associated with formation
      of RBC autoantibodies, such as a malignancy or (systemic) autoimmune disease. Currently,
      there are no guidelines to follow-up DAT positive donors.

      A second unsolved difficulty is the choice of treatment in AIHA. Hemolysis can be stopped or
      at least attenuated with corticosteroids, aiming to inhibit autoantibody production and/or
      RBC destruction. Many patients do not respond adequately to corticosteroid treatment or
      develop severe side effects.

      Currently, it is advised to avoid RBC transfusions since these may lead to aggravation of
      hemolysis and RBC alloantibody formation. But in case symptomatic anemia occurs, RBC
      transfusions need to be given. An evidence-based transfusion strategy for AIHA patients is
      needed to warrant safe transfusion in this complex patient group.

      To design optimal diagnostic testing and (supportive) treatment algorithms, the investigators
      will study a group well-characterized patients with AIHA and blood donors without AIHA, via a
      prospective centralized clinical data collection and evaluation of new laboratory tests. With
      this data the knowledge of the AIHA pathophysiology and to evaluate diagnostic testing in
      correlation with clinical features and treatment outcome can be improved.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Immunological characteristics of autoantibodies in autoimmune hemolytic anemia (AIHA) patients - laboratory tests.</measure>
    <time_frame>12-18 months</time_frame>
    <description>Documentation of characteristics of autoantibodies (e.g. isotype, subtype, titer, thermal amplitude).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of hemolysis before and after therapy, reported per class of auto-immune hemolytic anemia. - laboratory tests</measure>
    <time_frame>12-18 months</time_frame>
    <description>Documentation of hemolysis parameters (hemoglobin level (g/dL), reticulocytes (%), haptoglobin (mg/dL), bilirubin (μmol/L) and LDH(U/L)) before and after each type of therapy. AIHA classification as IgG/IgA only, IgG/IgA with complement activation or complement activation only.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of underlying disease that causes or is associated with AIHA.</measure>
    <time_frame>12-18 months</time_frame>
    <description>Documentation of physician-reported underlying disease that caused AIHA (e.g. autoimmune and/or lymphoproliferative disease, infection, medication).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of treatment prescribed as first-line, second-line or further-line treatment for AIHA.</measure>
    <time_frame>12-18 months</time_frame>
    <description>The percentage of patients receiving first, second or further-line treatment for AIHA will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematological response after each treatment line (CR, CR-u, PR and NR)</measure>
    <time_frame>12-18 months</time_frame>
    <description>Percentage of patients with CR, CR-u, PR and NR after each treatment line. Hematological response will be classified as CR (complete remission), CR-u (CR- undetermined), PR (partial response) and NR (no response).
CR: normal hemoglobin, no signs of hemolysis (normal haptoglobin, normal amount of reticulocytes, bilirubin, LDH), no treatment and transfusion independence during the last 4 weeks.
CR-u: as CR, but hemoglobin, reticulocytes, LDH and/or bilirubin are deviating through another reason (e.g. underlying malignant disease).
PR: 1. Hemoglobin &gt; 10g/dL, no signs of hemolysis, transfusion independent, but a continuous treatment with low dose prednisone (&lt; 10 mg/day) or other immunosuppressive therapy is necessary. 2. Compensated hemolytic anemia with an stable hemoglobin &gt;10g/dL, transfusion independent, maximal dose of prednisone &lt; 10mg/day or other continuous immunosuppressive therapy or EPO.
NR: no PR reached</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival, defined as the time since the achievement of complete or partial remission until relapse of AIHA or dead from any cause.</measure>
    <time_frame>12-18 month</time_frame>
    <description>Relapse-free survival will be calculated as the time since the achievement of complete or partial remission until relapse of AIHA or dead from any cause. Median RFS and 95% CI will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Documentation of adverse events during the treatment of AIHA.</measure>
    <time_frame>12-18 month</time_frame>
    <description>Documentation of adverse events during the treatment of AIHA indicated according to the Common Terminology Criteria for Adverse Events v4.0 (CTCAE) Publish Date: May 28, 2009</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of hemolysis parameters after red blood cell transfusion.</measure>
    <time_frame>1 and 7 days after transfusion</time_frame>
    <description>Documentation of hemolysis parameters (hemoglobin level (g/dL), reticulocytes (%), haptoglobin (mg/dL), bilirubin (μmol/L) and LDH (U/L)) before red blood cell transfusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the incidence of auto- and alloantibodies after red blood cell transfusion.</measure>
    <time_frame>12-18 months</time_frame>
    <description>Compare the incidence of auto- and alloantibodies before and after red blood cell transfusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of autoantibodies of DAT positive blood donors.</measure>
    <time_frame>12-18 months</time_frame>
    <description>Documentation of characteristics of autoantibodies (e.g. isotype, subtype, titer, thermal amplitude) of DAT positive blood donors.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">720</enrollment>
  <condition>Autoimmune Hemolytic Anemia</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Patients with a positive DAT, a positive eluate and signs of hemolysis
Patients with a positive DAT with complement only, negative eluate, but with hemolysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blood donors</arm_group_label>
    <description>Blood donors with a positive direct antiglobulin test and a positive eluate and/or clinically relevant cold auto-antibodies</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples from patients (older than 16 years) and blood donors (older than 18 years) and
      urine samples from the first 20 included patients in each of the participating hospitals,
      will be collected for experimental diagnostic testing at inclusion (T0) and after 1-1,5 year
      (T1) of follow-up.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients, from the age of 3 months, with a positive DAT a positive eluate and signs of
        hemolysis and patients with a positive DAT for complement only with a negative eluate but
        with signs of hemolysis, and blood donors with a positive DAT and a positive eluate and/or
        clinically relevant cold autoantibodies.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sufficient comprehension of the Dutch language

          -  Signed informed consent by patient and/or parent/caretaker or donor

          -  Patients older than 3 months

          -  Patients with a positive DAT, a positive eluate and signs of hemolysis*

          -  Patients with a positive DAT with complement only, negative eluate, but with signs of
             hemolysis

          -  Donors with a (repeatedly) positive DAT and a positive eluate and/or clinically
             relevant cold auto-antibodies

        Exclusion Criteria:

          -  Prior inclusion in the DRAIHA study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. De Haas, Prof. MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Clinical Transfusion Research (CCTR), Sanquin, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>S.S Zeerleder, Prof. MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, University of Bern, Switzerland and Department for BioMedical Research, University of Bern, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>M. Jalink, MD</last_name>
    <phone>+31205123373</phone>
    <email>m.jalink@sanquin.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Masja De Haas, Prof. MD PhD</last_name>
    <phone>+31205123373</phone>
    <email>m.dehaas@sanquin.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam-Zuidoost</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMC Radboud</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Garratty G. Immune hemolytic anemia associated with negative routine serology. Semin Hematol. 2005 Jul;42(3):156-64. Review.</citation>
    <PMID>16041665</PMID>
  </reference>
  <reference>
    <citation>Freedman J. False-positive antiglobulin tests in healthy subjects and in hospital patients. J Clin Pathol. 1979 Oct;32(10):1014-8.</citation>
    <PMID>521494</PMID>
  </reference>
  <reference>
    <citation>Barcellini W, Fattizzo B, Zaninoni A, Radice T, Nichele I, Di Bona E, Lunghi M, Tassinari C, Alfinito F, Ferrari A, Leporace AP, Niscola P, Carpenedo M, Boschetti C, Revelli N, Villa MA, Consonni D, Scaramucci L, De Fabritiis P, Tagariello G, Gaidano G, Rodeghiero F, Cortelezzi A, Zanella A. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014 Nov 6;124(19):2930-6. doi: 10.1182/blood-2014-06-583021. Epub 2014 Sep 16.</citation>
    <PMID>25232059</PMID>
  </reference>
  <reference>
    <citation>Rottenberg Y, Yahalom V, Shinar E, Barchana M, Adler B, Paltiel O. Blood donors with positive direct antiglobulin tests are at increased risk for cancer. Transfusion. 2009 May;49(5):838-42. doi: 10.1111/j.1537-2995.2008.02054.x. Epub 2009 Jan 2.</citation>
    <PMID>19170992</PMID>
  </reference>
  <reference>
    <citation>Meulenbroek EM, de Haas M, Brouwer C, Folman C, Zeerleder SS, Wouters D. Complement deposition in autoimmune hemolytic anemia is a footprint for difficult-to-detect IgM autoantibodies. Haematologica. 2015 Nov;100(11):1407-14. doi: 10.3324/haematol.2015.128991. Epub 2015 Sep 9.</citation>
    <PMID>26354757</PMID>
  </reference>
  <reference>
    <citation>Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. Haematologica. 2014 Oct;99(10):1547-54. doi: 10.3324/haematol.2014.114561. Review.</citation>
    <PMID>25271314</PMID>
  </reference>
  <reference>
    <citation>Reynaud Q, Durieu I, Dutertre M, Ledochowski S, Durupt S, Michallet AS, Vital-Durand D, Lega JC. Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies. Autoimmun Rev. 2015 Apr;14(4):304-13. doi: 10.1016/j.autrev.2014.11.014. Epub 2014 Dec 9.</citation>
    <PMID>25497766</PMID>
  </reference>
  <reference>
    <citation>Shi J, Rose EL, Singh A, Hussain S, Stagliano NE, Parry GC, Panicker S. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood. 2014 Jun 26;123(26):4015-22. doi: 10.1182/blood-2014-02-556027. Epub 2014 Apr 2.</citation>
    <PMID>24695853</PMID>
  </reference>
  <reference>
    <citation>Wouters D, Stephan F, Strengers P, de Haas M, Brouwer C, Hagenbeek A, van Oers MH, Zeerleder S. C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia. Blood. 2013 Feb 14;121(7):1242-4. doi: 10.1182/blood-2012-11-467209.</citation>
    <PMID>23411737</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>July 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2019</study_first_posted>
  <last_update_submitted>July 17, 2019</last_update_submitted>
  <last_update_submitted_qc>July 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

